There's Reason For Concern Over Keymed Biosciences Inc.'s (HKG:2162) Massive 28% Price Jump
May 13
Hong Kong (HSI) Biotech Industry Analysis
UpdatedAug 03, 2024
DataAggregated Company Financials
Companies48
- 7D2.4%
- 3M-13.8%
- 1Y-32.2%
- YTD-20.6%
In the last week, the Biotech industry is up 2.4%, with Sichuan Kelun-Biotech Biopharmaceutical leading the way, up 3.5%. During this same period, the Cutia Therapeutics underperformed, falling 8.2%. In the past year, the industry is down 32%. Earnings are forecast to grow by 34% annually.
Industry Valuation and Performance
Has the Hong Kong Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sat, 03 Aug 2024 | HK$321.6b | HK$50.0b | -HK$19,621,133,103.77 | 11.6x | -16.4x | 6.4x |
| Mon, 01 Jul 2024 | HK$327.6b | HK$49.6b | -HK$19,441,769,600.62 | 12.1x | -16.9x | 6.6x |
| Wed, 29 May 2024 | HK$338.7b | HK$49.8b | -HK$19,505,887,561.30 | 11.3x | -17.4x | 6.8x |
| Fri, 26 Apr 2024 | HK$346.9b | HK$49.5b | -HK$19,469,847,113.03 | 11.8x | -17.8x | 7x |
| Sun, 24 Mar 2024 | HK$345.6b | HK$49.7b | -HK$19,699,938,439.12 | 14.1x | -17.5x | 7x |
| Tue, 20 Feb 2024 | HK$329.9b | HK$46.8b | -HK$20,168,860,809.96 | 16.4x | -16.4x | 7.1x |
| Thu, 18 Jan 2024 | HK$354.3b | HK$46.8b | -HK$20,184,432,385.00 | 17x | -17.6x | 7.6x |
| Sat, 16 Dec 2023 | HK$406.3b | HK$47.2b | -HK$20,376,104,618.00 | 17.9x | -19.9x | 8.6x |
| Mon, 13 Nov 2023 | HK$417.3b | HK$45.2b | -HK$18,924,858,618.00 | 13.5x | -22.1x | 9.2x |
| Wed, 11 Oct 2023 | HK$380.4b | HK$44.9b | -HK$19,115,913,057.00 | 13.3x | -19.9x | 8.5x |
| Fri, 08 Sep 2023 | HK$400.2b | HK$44.9b | -HK$18,889,389,617.00 | 15.3x | -21.2x | 8.9x |
| Sun, 06 Aug 2023 | HK$398.2b | HK$35.6b | -HK$23,393,254,800.00 | 22.3x | -17x | 11.2x |
| Tue, 04 Jul 2023 | HK$392.4b | HK$35.3b | -HK$23,202,884,962.00 | 25.7x | -16.9x | 11.1x |
| Thu, 01 Jun 2023 | HK$412.8b | HK$35.9b | -HK$23,645,687,154.00 | 26.8x | -17.5x | 11.5x |
| Sat, 29 Apr 2023 | HK$445.1b | HK$36.9b | -HK$23,365,935,236.00 | 17.8x | -19.1x | 12.1x |
| Mon, 27 Mar 2023 | HK$430.5b | HK$35.1b | -HK$35,058,747,287.00 | 22.5x | -12.3x | 12.3x |
| Wed, 22 Feb 2023 | HK$417.7b | HK$34.5b | -HK$34,860,112,837.00 | 33.1x | -12x | 12.1x |
| Fri, 20 Jan 2023 | HK$449.5b | HK$34.9b | -HK$35,241,637,476.00 | 29.4x | -12.8x | 12.9x |
| Sun, 18 Dec 2022 | HK$394.6b | HK$33.6b | -HK$33,868,975,451.00 | 24.3x | -11.7x | 11.8x |
| Tue, 15 Nov 2022 | HK$375.3b | HK$33.2b | -HK$33,509,711,772.00 | 17.2x | -11.2x | 11.3x |
| Thu, 13 Oct 2022 | HK$274.0b | HK$33.8b | -HK$32,318,825,304.00 | 15.6x | -8.5x | 8.1x |
| Sat, 10 Sep 2022 | HK$355.8b | HK$34.3b | -HK$33,625,291,716.00 | 17x | -10.6x | 10.4x |
| Mon, 08 Aug 2022 | HK$337.2b | HK$32.8b | -HK$46,282,522,083.00 | 12.1x | -7.3x | 10.3x |
| Wed, 06 Jul 2022 | HK$382.7b | HK$33.1b | -HK$46,626,033,002.00 | 15.1x | -8.2x | 11.6x |
| Fri, 03 Jun 2022 | HK$323.7b | HK$34.2b | -HK$46,119,353,466.00 | 13.1x | -7x | 9.5x |
| Sun, 01 May 2022 | HK$337.9b | HK$35.5b | -HK$44,796,407,626.00 | 13.3x | -7.5x | 9.5x |
| Tue, 29 Mar 2022 | HK$328.9b | HK$36.1b | -HK$38,875,100,995.00 | 13.2x | -8.5x | 9.1x |
| Thu, 24 Feb 2022 | HK$331.0b | HK$33.0b | -HK$31,387,875,444.00 | 13.2x | -10.5x | 10x |
| Sat, 22 Jan 2022 | HK$361.7b | HK$31.2b | -HK$31,905,520,771.00 | 13.1x | -11.3x | 11.6x |
| Mon, 20 Dec 2021 | HK$427.4b | HK$31.1b | -HK$31,807,684,351.00 | 13.6x | -13.4x | 13.8x |
| Wed, 17 Nov 2021 | HK$499.8b | HK$31.0b | -HK$31,715,065,788.00 | 13.9x | -15.8x | 16.1x |
| Fri, 15 Oct 2021 | HK$494.8b | HK$30.6b | -HK$31,600,234,295.00 | 14.5x | -15.7x | 16.2x |
| Sun, 12 Sep 2021 | HK$528.3b | HK$30.4b | -HK$31,412,511,864.39 | 17.6x | -16.8x | 17.4x |
| Tue, 10 Aug 2021 | HK$579.3b | HK$30.2b | -HK$32,058,827,347.35 | 14.6x | -18.1x | 19.2x |
Price to Earnings Ratio
-18.1x
Current Industry PE
- Investors are pessimistic on the Hong Kong Biotechs industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The 3-year average PS ratio of 10.6x is higher than the industry's current PS ratio of 6.4x.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have improved over the last three years.
- Revenues for these companies have grown 18% per year.
- This means that more sales are being generated by these companies overall, and subsequently losses are decreasing too.
Industry Trends
Which industries have driven the changes within the Hong Kong Healthcare industry?
| HK Market | -0.018% | |
| Healthcare | 1.13% | |
| Biotech | 2.40% | |
| Biotech | 2.40% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 6990 Sichuan Kelun-Biotech Biopharmaceutical | HK$154.60 | 3.5% +HK$1.2b | 108.9% | PS20.6x | |
| 9926 Akeso | HK$42.00 | 3.3% +HK$1.2b | 15.1% | PE16.5x | |
| 1541 ImmuneOnco Biopharmaceuticals (Shanghai) | HK$14.92 | 15.7% +HK$755.8m | n/a | PS657.5x | |
| 1877 Shanghai Junshi Biosciences | HK$12.12 | 5.8% +HK$650.0m | -48.0% | PS6.8x | |
| 1801 Innovent Biologics | HK$39.25 | 0.9% +HK$569.9m | 19.7% | PS9.5x |
